Industri

Morepen dispatches its first batch under CDMO mandate

Morepen Laboratories issued an update on its recently announced Rs. 825 crore C...

Ascension Saint Thomas Breaks Ground on Clarksville Hos...

Ascension Saint Thomas has started work on a new full-service hospital and integ...

Beyond the batch: How digital twins are rewriting the r...

Amit Malviya, VP – QA, Zest Pharma, highlights how digital twins, AI and real-t...

Anixa Biosciences secures Korean patent for breast canc...

The MOIP has issued Patent Number 10-2960889, providing protection for Anixa’s b...

Zymeworks agrees to buy Theravance Biopharma for $929m

Under the terms of the deal, Theravance Biopharma shareholders will receive $17 ...

Aurobindo Pharma USA completes acquisition of Lannett f...

Lannett becomes wholly owned subsidiary of APUSA and will operate as Lannett Co...

Nadda launches Drug Registry under ABDM to standardise ...

Platform developed with CDSCO and NRCeS includes over 123,000 branded drugs an...

Facility of the Month: Children’s Nebraska Behavioral H...

Children's Nebraska's new $114 million Behavioral Health & Wellness Center in Om...

FDA issues complete response letter to Sobi’s NASP for ...

The FDA has requested further information, primarily focusing on the manufacturi...

Lilly’s Jaypirca receives CHMP positive opinion for CLL...

This Jaypirca CHMP recommendation for CLL applies across all lines of therapy, r...

Strides partners with Ascent Capital to unlock value in...

Deal values Pivot Path at ~₹2.3 billion post-money; Strides to realise ~₹1 bill...

Alembic Pharmaceuticals gets USFDA approval for Dapsone...

Dapsone Gel is indicated for the topical treatment of acne vulgaris The post Al...

Self-Adjusting Hem Bar

For outdoor roller shade applications where uneven surfaces can create gaps, Dra...

Jamie Easterling Named President of Memorial Hospital o...

Beacon Health System announced that Jamie Easterling, MBA, has been named Presid...

Immunai and Boehringer partner to identify T-cell targets

The initial phase of the partnership, valued at up to $15m and running until 202...

Ionis grants Recordati rights to zilganersen for Alexan...

Ionis will retain the responsibility for commercialising the RNA-targeted medici...